Clinical and Prognostic Significance of CEBPA Mutations in Myelodysplastic Syndromes
Cancers · 01.07.2026 · 18 (13) · 2135
DOI: 10.3390/cancers18132135 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 01.07.2026. Verfasst von Mohamed M Khamis und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Mercy Hospital St. Louis, St. Louis, MO 63141, USA. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Myelodysplastic syndromes (MDS) carry a highly variable prognosis, stratified by the Revised International Prognostic Scoring System (IPSS-R) and the Molecular IPSS (IPSS-M). CEBPA mutations define a favorable-risk subgroup in acute myeloid leukemia (AML), yet their prognostic significance in MDS has not been characterized. Methods: We analyzed 2442 patients from the International Working Group (IWG) 2022 multi-center MDS registry after pre-specified exclusions. Overall survival (OS) and leukemia-free survival (LFS) were compared between CEBPA-mutated (n = 66; 2.7%) and wild-type patients using Kaplan–Meier estimation and Cox proportional hazards regression, adjusting for age, sex, and IPSS-R score; pre-specified subgroup, sensitivity, competing-risk, and mutation subtype analyses were performed. Results:CEBPA-mutated patients had markedly inferior OS (median 17.2 versus 42.2 months; HR 2.05, 95% CI 1.50–2.79; p < 0.001). After IPSS-R adjustment, the hazard ratio remained adverse (HR 1.39, 95% CI 1.00–1.94; p = 0.053), with uniform directionality across all 13 evaluable subgroups and no significant interaction. Co-mutation adjustment for ASXL1 and STAG2 further attenuated the hazard ratio to HR 1.11 (95% CI 0.79–1.57; p = 0.54), suggesting part of the observed signal reflects co-mutation burden rather than an independent CEBPA effect. Competing-risk analysis suggested that the excess mortality is mediated through AML transformation (CEBPA-mutated versus wild-type subdistribution hazard ratio of 1.89, 95% CI 1.20–2.99; p = 0.006) rather than non-transformative MDS mortality (cause-specific HR 0.97; p = 0.890). Truncating mutations drove the adverse signal (HR 2.21; p = 0.023), while basic leucine zipper (bZIP) domain mutations showed no significant effect (HR 1.25; p = 0.470). Conclusions:CEBPA mutations identify a rare MDS subgroup with markedly inferior survival, driven by truncating loss-of-function mutations and associated with leukemic transformation; the AML-derived bZIP-favorable paradigm does not translate to MDS, and CEBPA mutation status merits a prospective study to assess clinical utility for risk stratification.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Mercy Hospital St. Louis, St. Louis, MO 63141, USA.
- Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA.
- Division of Hematology/Oncology, University of Cincinnati College of Medicine, Cincinnati, OH 45227, USA.
- Hematology/Oncology, Blood and Marrow and Cellular Therapy Program, SSM Health Saint Louis University Hospital, St. Louis, MO 63104, USA.
ORCID-Profile: Mohamed M Khamis, Aref Al-Kali, Omar Alkharabsheh, Ranju Kunwor
Zitieren
APA
Khamis, M. M., Al-Kali, A., Alkharabsheh, O., Babic, A., & Kunwor, R. (2026). Clinical and Prognostic Significance of CEBPA Mutations in Myelodysplastic Syndromes. Cancers, 18(13), 2135. https://doi.org/10.3390/cancers18132135
Vancouver
Khamis MM, Al-Kali A, Alkharabsheh O, Babic A, Kunwor R. Clinical and Prognostic Significance of CEBPA Mutations in Myelodysplastic Syndromes. Cancers. 2026;18(13):2135. doi:10.3390/cancers18132135
BibTeX
@article{Khamis2026,
author = {Khamis, Mohamed M and Al-Kali, Aref and Alkharabsheh, Omar and Babic, Aleksandar and Kunwor, Ranju},
title = {Clinical and Prognostic Significance of CEBPA Mutations in Myelodysplastic Syndromes},
journal = {Cancers},
year = {2026},
volume = {18},
number = {13},
pages = {2135},
doi = {10.3390/cancers18132135}
}
EUVIMED